Trials / Completed
CompletedNCT01373164
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galunisertib | Administered orally |
| DRUG | Gemcitabine | Administered intravenously |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2015-11-01
- Completion
- 2016-12-01
- First posted
- 2011-06-14
- Last updated
- 2018-05-16
- Results posted
- 2018-05-16
Locations
24 sites across 6 countries: United States, Belgium, France, Germany, Italy, Spain
Source: ClinicalTrials.gov record NCT01373164. Inclusion in this directory is not an endorsement.